Studies Show GaM Inhibits Pediatric Tumor Growth

IQ-AI Ltd

("IQ-AI" or the "Company")

New Studies Show Oral Gallium Maltolate (GaM) Inhibits Pediatric Tumor Growth

Imaging Biometrics, LLC (IB), a wholly-owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCQB: IQAIF), is pleased to share the results of two pre-clinical studies that were presented at last week's 2023 Society of Neuro Oncology (SNO) Pediatric Conference in Washington, DC. Each study, led by Dr. Mona Al-Gizawiy, PhD from the Schmainda Lab at the Medical College of Wisconsin (MCW), demonstrated inhibitory effects of oral GaM in two types of pediatric brain tumors in vivo; atypical teratoid rhabdoid tumor (ATRT) and glioblastoma multiforme (GBM). Oral GaM is the same agent being investigated in adult GBM in IQ-AI's sponsored phase I clinical trial being conducted at MCW.

In 2022, it was estimated that approximately 5,500 new cases of brain tumors were diagnosed in children age 0-19 in the US. While rare, brain and other central nervous system (CNS) tumors still represent the largest cause of cancer-related death in that age group. Both ATRT and GBM are highly aggressive tumors that are associated with poor outcomes in children. The dire prognosis is due in part to the poor response to limited treatment options available.

The results of each study were consistent with previous in vitro work conducted in the Schmainda Lab showing tumor growth inhibition and a survival benefit from treatment with oral GaM. Median overall survival for ATRT was 89 days in the control group and 170 days in the treated group. For GBM, those numbers were 21 and 49 days, respectively. Both studies concluded that monotherapy with oral GaM profoundly inhibited growth and provided a significant survival benefit.

In April, IB applied for Orphan Drug Designation to the US Food and Drug Administration (FDA) for the use of GaM in pediatric brain tumors. The application is under review and, if granted, would support the development and evaluation of a new treatment alternative for an unmet clinical need.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC:  IB is a wholly-owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.